References
- Modlin I., Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997; 79: 813–829, [PUBMED], [INFOTRIEVE]
- Godwin J. Carcinoid tumors: an analysis of 2837 cases. Cancer 1975; 36: 560–569, [PUBMED], [INFOTRIEVE]
- Kulke M., Mayer R. Carcinoid tumors. N. Engl. J. Med. 1999; 340: 858–868, [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
- Kvols L., Moertel C. G., O'Connell M. J., Schutt A. J., Rubin J., Hahn R. G. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analog. N. Engl. J. Med. 1986; 315: 663–666, [PUBMED], [INFOTRIEVE]
- Rubin J., Ajani J., Schirmer W., Venook A. P., Bukowski R., Pommier R., Saltz L., Dandona P., Anthony L. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J. Clin. Oncol. 1999; 17: 600–666, [PUBMED], [INFOTRIEVE]
- DiBartolomeo M., Bajetta E., Buzzoni R., Mariani L., Carnaghi C., Somma L., Zilembo N., di Leo A. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. Cancer 1996; 77: 402–408, [CROSSREF]
- Oberg K., Eriksson B. The role of interferons in the management of carcinoid tumors. Acta Oncol. 1991; 30: 519–522, [PUBMED], [INFOTRIEVE]
- Moertel C., Hanley J. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin. Trials 1979; 2: 327–334, [PUBMED], [INFOTRIEVE]
- Engstrom P., Lavin P. T., Moertel C. G., Folsch E., Douglass H. O., Jr. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J. Clin. Oncol. 1984; 2: 1255–1259, [PUBMED], [INFOTRIEVE]
- Sparano J. A. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials. Clin. Breast Cancer 2000; 1: 32–40, [PUBMED], [INFOTRIEVE], [CSA]
- Posner M. R. Docetaxel in squamous cell cancer of the head and neck. Anticancer Drugs 2001; 12(suppl. 1)S21–S24, [PUBMED], [INFOTRIEVE]
- Georgoulias V. Docetaxel (taxotere) in the treatment of non-small cell lung cancer. Curr. Med. Chem. 2002; 9: 869–877, [PUBMED], [INFOTRIEVE]
- Kelly K. New chemotherapy agents for small cell lung cancer. Chest 2000; 117: 156S–162S, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Kaplan E., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 1959; 53: 457–481, [CSA]
- Moertel C. Treatment of the carcinoid tumor and the malignant carcinoid syndrome. J. Clin. Oncol. 1983; 1: 727–740, [PUBMED], [INFOTRIEVE]
- Bukowski R., Tangen C. M., Peterson R. F., Taylor S. A., Rinehart J. J., Eyre H. J., Rivkin S. E., Fleming T. R., Macdonald J. S. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. Cancer 1994; 73: 1505–1508, [PUBMED], [INFOTRIEVE]
- Feldman J., O'Dirisio T. Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am. J. Med. 1986; 81(suppl. 6B)41–48, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Quaedvlieg P., Visser O., Lamers C. B., Janssen-Heijen M. L., Taal B. G. Epidemiology and survival in patients with carcinoid disease in the Netherlands. Ann. Oncol. 2001; 12: 1295–1300, [PUBMED], [INFOTRIEVE], [CROSSREF]
- Ansell S., Pitot H. C., Burch P. A., Kvols L. K., Mahoney M. R., Rubin J. A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91: 1543–1548, [PUBMED], [INFOTRIEVE], [CROSSREF]